NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
Partnership co-promoting NovaBay’s Avenova® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™
Preparing for
Under the agreement,
“We are excited the
“Avenova is long established as the leading doctor-recommended hypochlorous-based lid and lash spray, making it ideal for our highly differentiated prescription ophthalmic product portfolio,” stated
Prescription Avenova is available through EyenoviaRx.com and Avenova.com. The non-prescription product is available directly to consumers through Amazon.com and other retailers.
About Clobetasol Propionate Ophthalmic Suspension, 0.05%
Clobetasol, developed by Formosa Pharmaceuticals, was granted
PLEASE GO TO CLOBETASOLBID.COM FOR IMPORTANT SAFETY INFORMATION for Clobetasol Proprionate Ophthalmic Suspension 0.05%
PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%
About Avenova
Manufactured in the
About
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
About
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. In addition to this Avenova OTC product line, NovaBay offers the Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in
Eyenovia Forward-Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology, and the potential market for clobetasol propionate ophthalmic suspension 0.05%. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the
In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our products and product candidates; the potential advantages of our products, product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our products and product candidates; our estimates regarding the potential market opportunity for our products and product candidates; reliance on third parties to develop and commercialize our products and product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products and product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws,
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701139750/en/
NovaBay Pharmaceuticals Contacts:
At the Company
Chief Executive Officer and General Counsel
510-899-8800
www.novabay.com
sales@novabay.com
E: @NovaBayPharma
Investor Contact
LHA Investor Relations
310-691-7100
jcain@lhai.com
Eyenovia Contacts:
At the Company
Chief Financial Officer
jgandolfo@eyenovia.com
Investor Contact
eric@lifesciadvisors.com
(646) 751-4363
Media Contact
Vice President, Commercial Operations
nlowe@eyenovia.com
Source: